Nascent Biotech, Inc. (OTCMKTS:NBIO – Get Free Report)’s share price crossed below its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $0.05 and traded as low as $0.05. Nascent Biotech shares last traded at $0.06, with a volume of 146,491 shares.
Nascent Biotech Trading Up 9.4 %
The stock has a 50 day moving average price of $0.05 and a two-hundred day moving average price of $0.07.
Nascent Biotech Company Profile
Nascent Biotech, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer.
Recommended Stories
- Five stocks we like better than Nascent Biotech
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- The 3 Best Retail Stocks to Shop for in August
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What is the Dow Jones Industrial Average (DJIA)?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Nascent Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nascent Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
